Sanofi to buy vitamin maker for $543M

In another instance of Big Pharma diversification, Sanofi-Aventis inked a deal to buy Primary Health Care's vitamin-making unit for $543.4 million; it's Australia's largest distributor of nutritional supplements. Release | Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.